Brillanti S - Search Results

1

Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.

Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Conti F, et al. Among authors: brillanti s. J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24. J Hepatol. 2016. PMID: 27349488

2

Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.

Brillanti S, Miglioli M, Barbara L. Brillanti S, et al. J Hepatol. 1995;23 Suppl 2:13-5; discussion 15-6. J Hepatol. 1995. PMID: 8720288 Clinical Trial.

3

Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders.

Brillanti S, Foli M, Di Tomaso M, Gramantieri L, Masci C, Bolondi L. Brillanti S, et al. Ital J Gastroenterol Hepatol. 1999 Mar;31(2):130-4. Ital J Gastroenterol Hepatol. 1999. PMID: 10363198 Clinical Trial.

4

Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis.

Gramantieri L, Chieco P, Di Tomaso M, Masi L, Piscaglia F, Brillanti S, Gaiani S, Valgimigli M, Mazziotti A, Bolondi L. Gramantieri L, et al. Among authors: brillanti s. Clin Cancer Res. 1999 Nov;5(11):3468-75. Clin Cancer Res. 1999. PMID: 10589760

5

Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.

Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Brillanti S, et al. Hepatology. 2000 Sep;32(3):630-4. doi: 10.1053/jhep.2000.16235. Hepatology. 2000. PMID: 10960460 Clinical Trial.

6

Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?

Vivarelli M, Bellusci R, Cucchetti A, Cavrini G, De Ruvo N, Aden AA, La Barba G, Brillanti S, Cavallari A. Vivarelli M, et al. Among authors: brillanti s. Transplantation. 2002 Dec 27;74(12):1746-51. doi: 10.1097/00007890-200212270-00017. Transplantation. 2002. PMID: 12499891

7

Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study.

Lodato F, Azzaroli F, Brillanti S, Colecchia A, Tamé MR, Montagnani M, Muratori R, Giovanelli S, Feletti V, Bacchi Reggiani ML, Roda E, Mazzella G. Lodato F, et al. Among authors: brillanti s. J Viral Hepat. 2005 Sep;12(5):536-42. doi: 10.1111/j.1365-2893.2005.00638.x. J Viral Hepat. 2005. PMID: 16108771 Clinical Trial.

8

Ribavirin for chronic hepatitis C: and the mystery goes on.

Brillanti S, Mazzella G, Roda E. Brillanti S, et al. Dig Liver Dis. 2011 Jun;43(6):425-30. doi: 10.1016/j.dld.2010.10.007. Epub 2010 Nov 18. Dig Liver Dis. 2011. PMID: 21093391 Review.

9

Severe acute autoimmune hepatitis after natalizumab treatment.

Lisotti A, Azzaroli F, Brillanti S, Mazzella G. Lisotti A, et al. Among authors: brillanti s. Dig Liver Dis. 2012 Apr;44(4):356-7. doi: 10.1016/j.dld.2011.11.003. Epub 2011 Dec 11. Dig Liver Dis. 2012. PMID: 22154948 No abstract available.

10

Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.

Conti F, Brillanti S, Buonfiglioli F, Vukotic R, Morelli MC, Lalanne C, Massari M, Foschi FG, Bernabucci V, Serio I, Prati GM, Negri E, Badia L, Caraceni P, Muratori P, Vitale G, Porro A, Morotti M, Mazzella G, Andreone P. Conti F, et al. Among authors: brillanti s. J Viral Hepat. 2017 Jun;24(6):454-463. doi: 10.1111/jvh.12663. Epub 2017 Feb 2. J Viral Hepat. 2017. PMID: 27976461

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

44 results

Search Page